In a male patient taking 25 mg metoprolol succinate (extended‑release) once daily for hypertension and palpitations with persistent symptoms, anxiety, and tremor despite current anxiolytic/antidepressant therapy, is it appropriate to add a 12.5 mg metoprolol tartrate (immediate‑release) dose as needed once daily for symptom control?

Increasing the Metoprolol Succinate Dose is More Appropriate Than Adding PRN Metoprolol Tartrate

Rather than adding a separate PRN dose of metoprolol tartrate, you should uptitrate the existing metoprolol succinate extended-release to achieve better 24-hour symptom control. The current 25 mg daily dose is subtherapeutic, and the FDA-approved dosing allows titration up to 400 mg daily for hypertension 1.

Why Uptitration of Metoprolol Succinate is Preferred

Pharmacokinetic Rationale

Metoprolol succinate extended-release is specifically designed to provide relatively constant plasma concentrations over 20 hours through a controlled-release pellet system 2. This formulation maintains steady beta-1 blockade throughout the day, which is ideal for managing both hypertension and palpitations that occur unpredictably.

In contrast, metoprolol tartrate has a much shorter duration of action (6-8 hours) 3. Adding a PRN dose creates several problems:

• Unpredictable overlap with the extended-release formulation, risking excessive beta-blockade
• Inconsistent plasma levels that defeat the purpose of using an extended-release product
• Potential for excessive bradycardia when both formulations are active simultaneously

Evidence-Based Dosing Strategy

Start by doubling the metoprolol succinate dose to 50 mg daily. The FDA label explicitly states that doses should be increased at weekly intervals until optimal blood pressure reduction is achieved 1. For hypertension, the usual initial dosage range is 25-100 mg daily, with your patient currently at the low end.

Guidelines support beta-blocker use for symptomatic tachyarrhythmias, with metoprolol succinate specifically studied at doses up to 95 mg daily for inappropriate sinus tachycardia 4. The 2016 ACC/AHA/HRS guideline notes that beta-blockers are "modestly effective in lowering heart rate and improving symptoms" in patients with palpitations 4.

Titration Protocol

1. Increase to 50 mg metoprolol succinate daily and reassess after 1 week

2. If symptoms persist, increase to 100 mg daily (the typical maintenance dose for hypertension) 1

3. Continue weekly uptitration as needed, monitoring for:

   • Heart rate (target resting HR 50-60 bpm per post-MI guidelines, though this can be individualized) 5
   • Blood pressure response
   • Symptom improvement
   • Adverse effects (fatigue, dizziness, bradycardia)

4. Maximum dose is 400 mg daily, though most patients respond to 100-200 mg 1

Critical Safety Considerations

Drug Interactions with Antidepressants

This is a crucial concern. You mention the patient is on medications for anxiety and depression. If he is taking paroxetine, fluoxetine, or bupropion, these are potent CYP2D6 inhibitors that increase metoprolol bioavailability 4-6 fold 6. Severe bradycardia and AV block have been reported with this combination 6.

• If on paroxetine, fluoxetine, or bupropion: Consider switching to a different beta-blocker not metabolized by CYP2D6 (like atenolol or bisoprolol), or switch the antidepressant to sertraline, venlafaxine, mirtazapine, or mianserin 6
• If on citalopram, escitalopram, or duloxetine: These cause 2-3 fold increases in metoprolol levels—use lower doses and monitor closely 6
• If on sertraline, venlafaxine, mirtazapine, or mianserin: No significant interaction expected 6

Monitoring Parameters

Before each dose increase, check:

• Resting heart rate (hold if <50 bpm unless patient is asymptomatic)
• Blood pressure (hold if systolic <90 mmHg)
• Symptoms of heart failure (though unlikely in this young patient)
• PR interval on ECG if available (avoid if >0.24 seconds) 3

Why Not PRN Metoprolol Tartrate?

The concept of "PRN once daily" is pharmacologically problematic. PRN medications are for acute, intermittent symptoms, but you're describing daily use. If symptoms occur daily, this indicates inadequate baseline control requiring scheduled medication adjustment, not PRN dosing.

Additionally, combining extended-release and immediate-release formulations of the same drug creates:

• Unpredictable pharmacokinetics with variable peak levels
• Risk of cumulative toxicity (bradycardia, hypotension, fatigue)
• Difficulty determining which formulation is effective or causing side effects

The 2013 STEMI guidelines show metoprolol tartrate is used for acute situations (IV then oral transition), not as PRN add-on to existing beta-blocker therapy 3.

Alternative Considerations

If uptitration of metoprolol succinate to adequate doses (100-200 mg) fails to control symptoms:

1. Verify medication adherence and proper timing (with or immediately after meals) 1
2. Rule out secondary causes of palpitations (hyperthyroidism, anemia, caffeine excess)
3. Consider adding ivabradine if heart rate remains elevated despite beta-blockade (though this is typically reserved for heart failure or inappropriate sinus tachycardia) 4
4. Optimize anxiety/depression management, as undertreated psychiatric conditions can manifest as palpitations and tremor
5. Consider switching to a different beta-blocker if drug interactions are limiting metoprolol dosing

The tremor you mention may actually improve with higher metoprolol doses, as beta-blockers are effective for essential tremor, particularly in blunting the response to stress 7.